Company

IGM Biosciences, Inc.

Headquarters: Mountain View, CA, United States

Employees: 171

CEO: Mr. Fred M. Schwarzer

NASDAQ: IGMS -7.71%

Market Cap

$590.4 Million

USD as of Jan. 1, 2024

Market Cap History

IGM Biosciences, Inc. market capitalization over time

Evolution of IGM Biosciences, Inc. market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of IGM Biosciences, Inc.

Detailed Description

IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of multiple diseases. Its lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 1 clinical trials to treat patients with relapsed/refractory B cell Non-Hodgkin's lymphoma (NHL). The company is also developing IGM-8444, an IgM antibody, which is in Phase 1 clinical trials for the treatment of patients with solid cancers and NHL; and IGM-7354, is a bispecific IgM antibody delivering interleukin-15 cytokines to PD-L1 expressing cells for use in the treatment of patients with solid and hematologic malignancies. It has a strategic research and license agreement with AbCellera to discover and develop IgM antibodies; and license agreement with AvantGen Inc. for various antibodies against the SARS-CoV-2 virus. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.

Top 1-year algo backtest: +269.94%

$10,000 in May 2023 would now be $36,994 by following this algorithm daily at market close.

Boost your stocks returns with Disfold AI... Now!

Try Disfold AI for FREE

Stocks & Indices

IGM Biosciences, Inc. has the following listings and related stock indices.


Stock: NASDAQ: IGMS wb_incandescent

Stock: FSX: 1K0 wb_incandescent

Details

Headquarters:

325 East Middlefield Road

Mountain View, CA 94043

United States

Phone: 650 965 7873